

- 9 Goodman L. Alzheimer's disease: a clinicopathologic analysis of twenty-three cases with a theory on pathogenesis. *J Nerv Ment Dis* 1953;117:97-130.
- 10 Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. *J Neurol Sci* 1970;11:205-42.
- 11 Kemper T. Neuroanatomical and neuropathological changes in normal aging and in dementia. In: Albert ML, ed. *Clinical Neurology of Aging*, Oxford (New York), 1984:9-52.
- 12 Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. *Arch Gerontol Geriatr* 1987;6:193-208.
- 13 Smith WT, Turner E, Sim M. Cerebral biopsy in the investigation of presenile dementia. II. Pathological aspects. *Br J Psychiatry* 1966; 112:127-33.
- 14 Todorov AB, Go RCP, Constantinidis J, Elston RC. Specificity of the clinical diagnosis of dementia. *J Neurol Sci* 1975;26:81-98.
- 15 Hughes CP, Myers FK, Smith K, Torack RM. Nosologic problems in dementia. *Neurology* 1973;23:344-51.
- 16 Sulkava R, Haltia M, Paetau A, et al. Accuracy of clinical diagnosis in primary degenerative dementia: correlation with neuropathological findings. *J Neurol Neurosurg Psychiatry* 1983;46:9-13.
- 17 Morris JC, Cole M, Banker BQ, Wright D. Hereditary dysphasic dementia and the Pick-Alzheimer spectrum. *Ann Neurol* 1984; 16:455-66.

*Neary replies:*

Dr Morris levels two criticisms of our paper, the one explicit and pathological, the other by implication and clinical. The former arises from his notion that the primary cortical atrophies represent a pathological continuum, with Pick's disease at one end of the spectrum, Alzheimer's disease at the other and non-specific encephalopathies representing an intermediate position, large cortical neuronal loss being the primary fundamental disorder.<sup>1</sup> An implication is that clinical differences in primary cortical atrophy are accidental and non-specific and that pathological diagnosis alone is primary. The argument does not address demographic, genetic and biochemical aspects of cerebral atrophy.

In our study comparison between DFT and proven Alzheimer's disease revealed differences along multiple dimensions: demographic, neurological, psychological, electrophysiological and neuroimaging. Double dissociations in clinical features such as the presence of conduct disorder and absence of spatial disability in DFT contrasting with the absence of conduct disorder and presence of spatial disability in Alzheimer's disease indicate that distinctions are not an artifact of disease severity. Furthermore,

longitudinal evaluation shows that distinctions are maintained despite progression of disease. The notion of "controlling for dementia severity" begs the question: it assumes that there is a common dimension of dementia along which patients can be equated.

Dr Morris cites the pathological findings of Brun in defining DFT,<sup>2</sup> revealing fronto-temporal cortical neuronal loss, spongiform change and gliosis in the absence of senile plaques and neurofibrillary tangles. He fails to point out that those pathological changes occurred in patients whom Brun and his colleagues in Southern Sweden have identified to be clinically distinct from Alzheimer's disease<sup>3,4</sup> and who exhibited a syndrome demographically and clinically identical to that of our DFT patients. Of 71 necropsied patients with Alzheimer's disease in Brun's study only two had such a clinical picture and a brunt of pathological change in the frontal lobes.

Since the publication of our paper four brains of patients with DFT have been studied at necropsy. All showed pathological change similar in nature and distribution to that described by Brun.<sup>2</sup> None had evidence of senile plaques or neurofibrillary tangles, or Pick cells.

The relationship between Pick's disease, DFT and focal cerebral atrophies is puzzling and intriguing. However, we see no grounds for accepting them as part of a spectrum with Alzheimer's disease, and consider the notion of a "continuum" to be heuristically sterile since it discourages the search for clinical, physiological, biochemical and genetic distinctions within the cerebral atrophies. It does, however, support the prevailing view that the dementia of the cerebral atrophies is a non-specific intellectual decline, and that distinct neuropsychological syndromes characterising different pathologies do not exist. Such a philosophy has we believe retarded research into dementia.

Dr Morris predicts that patients diagnosed as DFT will prove to have the pathology of Alzheimer's disease. In contrast, we predict that DFT will in the future be increasingly recognised as an entity distinct from Alzheimer's disease and with an incidence far higher than previously supposed.

**References**

- 1 Morris JC, Cole M, Banker BQ, Wright D. Hereditary dysphasic dementia and the Pick-Alzheimer spectrum. *Ann Neurol* 1984; 16:455-66.

- 2 Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. *Arch Gerontol Geriatr* 1987;6:193-208.
- 3 Gustafson L. Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. *Arch Gerontol Geriatr* 1987;6:209-23.
- 4 Risberg J. Frontal-lobe degeneration of non-Alzheimer type. III. Regional cerebral blood flow. *Arch Gerontol Geriatr* 1987;6:225-33.

**Olivopontocerebellar atrophy with neonatal onset**

Sir: I read with interest the article by Harding *et al*<sup>1</sup> on olivopontocerebellar atrophy (OPCA) with neonatal onset combined with systemic purine overproduction. The authors excluded two cases<sup>2,3</sup> presenting in the neonatal period that I had considered as OPCAs.<sup>4</sup> Gross and Kaltenbach's case is not classified as OPCA because "the cerebellar cortex was hardly affected whereas the dentate nuclei and red nuclei were severely involved". Norman and Urich's first case is considered more akin to pontocerebellar hypoplasia. I would like to comment on this question.

The degree of atrophy of the cerebellar cortex in OPCA varies greatly.<sup>5</sup> It is generally held that the first systems to degenerate in this conditions are nuclei pontis, arcuate nuclei and inferior olives. The pontocerebellar atrophy, that probably is the result of an anterograde transsynaptic degenerative phenomenon,<sup>6</sup> follows at a later stage and may be minimal at death.<sup>5</sup> In fact, there are well documented adult cases with no lesions at the cerebellar cortex.<sup>7</sup> For these cases the eponym ponto-olivary atrophy<sup>6,7,10</sup> seems to be more appropriate than OPCA. On the other hand, detailed pathological studies constantly reveal associated lesions with OPCA dentate nuclei degeneration being one of the most frequent of them.<sup>4</sup> Therefore, the case described by Gross and Kaltenbach<sup>2</sup> should be classified, as these authors did, among OPCAs.

Together with neocerebellar hypoplasia, in Norman and Urich's first case there was systemic degeneration (loss of neurons and/or fibrillary gliosis) affecting the following structures: nuclei pontis and transverse fibres, inferior olives and their hilia and capsules, arcuate nuclei and external arcuate fibres, nuclei lateralis medullae, dentate nuclei, central matter of lateral lobes of the cerebellum, thalamus, hypothalamus and other brain-stem nuclei.<sup>3</sup> The authors compared their findings to those exhaustively